The first case of deceased donor liver transplantation for a patient with end-stage liver cirrhosis due to human immunodeficiency virus and hepatitis C virus coinfection in Japan

抄録

We previously reported that progression of liver cirrhosis is quicker and survival is dismal in patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection, especially when acquired in childhood through contaminated blood product. Recently, we performed the first deceased donor liver transplantation (DDLT) for an HIV/HCV-coinfected hemophilic patient in Japan. A 40-year-old male was referred to our hospital for liver transplantation. Regular DDLT was performed using the piggyback technique with full size liver graft. Cold ischemia time was 465 minutes, and the graft liver weighed 1590 g. Pretransplant conversion of antiretroviral therapy (ART) was performed from Darunavir/Ritonavir to Raltegravir for flexible usage of calcineurin inihibitor postoperatively with Tenofovir. The postoperative course was uneventful, and he was discharged home on day 43and started anti-HCV treatment on day 110 with Pegylated-interferon, ribavirin and simeprevir after the DDLT. Herein we report the first case of DDLT in Japan. Meticulous management of ART and clotting factors could lead to the success of DDLT.